BEIGENE-BGB-16673-104
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination with Other Agents in Patients with Relapsed or Refractory B-Cell Malignancies
BEONE-BGB-11417-304
Phase III
OPEN TO ACCRUAL
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Patient With Previously Untreated Chronic Lymphocytic Leukemia
CARNABIOSCIENCES-C1763102
Phase I
OPEN TO ACCRUAL
A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non Hodgkin Lymphoma
IIT-SHAH-IL7-IL15-CD20-19
Phase I/II
OPEN TO ACCRUAL
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies